Induction of angiotensin-converting enzyme after miR-143/145 deletion is critical for impaired smooth muscle contractility

Diana Dahan,1* Mari Ekman,2* Anna-Karin Larsson-Callerfelt,1 Karolina Turczyńska,1 Thomas Boettger,3 Thomas Braun,3 Karl Swärd,1* and Sebastian Albinsson 1*

1Department of Experimental Medical Science, Lund University, Lund, Sweden; 2Department of Biology, Lund University, Lund, Sweden; and 3Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany

Submitted 15 July 2014; accepted in final form 23 September 2014


MicroRNAs have emerged as regulators of smooth muscle cell phenotype with a role in smooth muscle-related disease. Studies have shown that miR-143 and miR-145 are the most highly expressed microRNAs in smooth muscle cells, controlling differentiation and function. The effect of miR-143/145 knockout has been established in the vasculature but not in smooth muscle from other organs. Using knockout mice we found that maximal contraction induced by either depolarization or phosphatase inhibition was reduced in vascular and airway smooth muscle but maintained in the urinary bladder. Furthermore, a reduction of media thickness and reduced expression of differentiation markers was seen in the aorta but not in the bladder. Supporting the view that phenotype switching depends on a tissue-specific target of miR-143/145, we found induction of angiotensin-converting enzyme in the aorta but not in the bladder where angiotensin-converting enzyme was expressed at a low level. Chronic treatment with angiotensin type-1 receptor antagonist restored contractility in miR-143/145-deficient aorta while leaving bladder contractility unaffected. This shows that tissue-specific targets are critical for the effects of miR-143/145 on smooth muscle differentiation and that angiotensin converting enzyme is one such target.

angiotensin II; contractile protein; microRNA; smooth muscle; vascular biology; detrusor; airway; urinary bladder; miR-145; myocardin

SMOOTH MUSCLE CELLS PLAY an important role in the formation and function of the cardiovascular, digestive, respiratory, and urinary systems. The ability of smooth muscle cells to contract and relax is crucial for the regulation of blood pressure, for peristaltic movements in the gut, and for micturition. Furthermore, smooth muscle cells can modulate their phenotype to a less contractile, more proliferative and migratory state in response to local environmental cues (30). This phenotype, often referred to as “synthetic,” is associated with decreased expression of contractile markers and increased synthesis of extracellular matrix proteins.

Recently, microRNAs (miRNAs) have emerged as regulators of smooth muscle cell phenotype with important roles in disease progression (5, 6). miRNAs are short noncoding RNAs (18–25 nucleotides long) with complementarity to sequences in target mRNAs (7). Biogenesis of most miRNAs requires the endonuclease dicer, which cleaves a pre-miRNA to generate a mature miRNA that in turn regulates mRNA stability and protein translation. Since hundreds of miRNAs are expressed in a cell, most signaling pathways are controlled by this class of RNAs. miRNAs show promise as therapeutic targets as they can be manipulated using mimics and inhibitors (36).

Several studies have shown that miR-143 and miR-145 are among the most highly expressed miRNAs in differentiated smooth muscle (8, 10, 11, 32, 39). They are encoded by a bicistronic miRNA cluster regulated by the transcription factor serum response factor (SRF) and its cofactors myocardin and myocardin-related transcription factors (MRTFs) (11, 24, 39). The expression of both miR-143 and miR-145 is downregulated in phenotypically modulated smooth muscle cell following vascular injury (10, 11). Furthermore, while both miR-143 and miR-145 are thought to be involved in the regulation of smooth muscle proliferation and migration (15, 39), it is primarily miR-145 that promotes contractile differentiation of vascular smooth muscle (5). Several mechanisms have been proposed for miR-145-dependent regulation of vascular smooth muscle differentiation, including direct or indirect upregulation of myocardin (10, 11), regulation of actin polymerization (3, 39), and control of calcium signaling (33, 34). Furthermore, miR-145 regulates the expression of angiotensin-converting enzyme (ACE) and this was demonstrated to play a significant role for the effects of miR-143/145 knockout (KO) in vascular smooth muscle (8).

Using smooth muscle-specific and tamoxifen-inducible KO of dicer, we previously found that loss of miRNAs impairs smooth muscle cell differentiation in the aorta, leading to reduced contractility and blood pressure (4). Using the same mouse model, we also demonstrated impaired depolarization-induced contraction in the urinary bladder (32). Expression of smooth muscle differentiation markers was, however, hardly affected in the bladder, contrasting with our findings in the aorta. Possible explanations for this discrepancy include the presence of miRNAs that repress differentiation in bladder smooth muscle cells. Alternatively, miRNAs with an established role in smooth muscle differentiation, such as miR-143/145, may act on targets that are unique for the vasculature. Here we addressed this possibility by comparing contractility and differentiation in aorta, airways, and urinary bladder from miR-143/145 KO mice. While contractility and differentiation were diminished in aorta, loss of miR-143/145 had no effect on bladder contractility and increased rather than decreased expression of differentiation markers. These effects correlated...
with induction of ACE, which was expressed at a low level and not induced in the bladder of KO mice. Finally, blockade of angiotensin receptors rescued contractility in the aorta but was without effect in the bladder, arguing that ACE is a key target for miR-143/145-dependent phenotype switching in smooth muscle cells.

**EXPERIMENTAL PROCEDURES**

*Animals.* All animal experiments were approved by the Malmö/Lund Animal Ethics Committee (M167-09, M287-12). The miR-143/145 KO mice were generated at the Max-Planck-Institute for Heart and Lung Research as described previously (8) and bred in-house.

**β-Galactosidase staining.** To generate KO mice, the miR-143/145 locus was targeted with a vector containing the LacZ reporter (8). β-Galactosidase activity was used as a reporter of miR-143/145 expression. Microdissected organs from male and female heterozygous mice were fixed in 4% paraformaldehyde in phosphate-buffered saline (pH 7.0) for 10 min at 4°C. Organs were then incubated with continuous shaking in X-gal staining solution (150 mM NaCl, 2 mM MgCl₂, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 40 mM citric acid, and 12 mM sodium phosphate pH 6.0) containing 1 mg/mL X-gal (Sigma, St. Louis, MO) at 37°C overnight. Photographs were acquired with an Infinity 1 camera mounted on an Olympus (SZ61) microscope.

**Hemodynamic measurements.** Systemic blood pressure was recorded using tail cuffs (CODA Non-invasive Blood Pressure System;Kent Scientific) as described previously (4). Animals were trained for 5 consecutive days before blood pressure recordings. The blood pressure of each animal was then recorded three times.

**Isometric force measurements.** Aortic and tracheal rings and bladder strips (1.5–2 mm in length) were mounted in a Multivana myograph (610M; Danish Myo Technology) and bathed in HEPES-buffered Kreb’s solution (in mM: 135.5 NaCl, 5.9 KCl, 2.5 CaCl₂, 1.2 MgCl₂, and 11.6 HEPES pH 7.4) at 37°C. During an equilibration period of 30 min, the preparations were stretched to a stable passive tension of 5 mN (aorta), 1 mN (trachea), and 8 mN (bladder). After this period, each experiment was started by exposing the preparations twice to 60 mM KC¹-containing HEPES solution. Following each contraction, preparations were relaxed in normal HEPES buffer. Cumulative concentration-responses curves for cirazoline and angiotensin II (aorta) or carbachol (bladder, trachea) were generated. At the end of concentration-responses curves for cirazoline and angiotensin II preparations were relaxed in normal HEPES buffer. Cumulative doses of carbachol were maintained for 7 min. Images were analyzed using NIS-Elements software.

**Western blot.** Aorta and bladder were excised, cleaned, and quickly frozen in liquid nitrogen. The samples were homogenized in SDS sample buffer (60 mM Tris·HCl pH 6.8, 2% SDS, and 10% glycerol) as previously described (32). The amount of protein was determined using Bio-Rad DC protein assay. Equal amounts (20 μg) of protein were loaded in the wells of Bio-Rad TGX 4–15% or Any KD Criterion gels and then transferred using wet transfer overnight. Proteins were detected using the following commercially available primary antibodies: heat shock protein-90 (HSP-90; 610418; BD Transduction Laboratories), ACE (ab39172p; Abcam), Rho kinase [ACC-003 no. 4035 (C8F7); Cell Signaling], KLF5 (ab24331; Abcam), KLF5 (ab24331; Abcam) phospho-LIM kinase (no. 3841; Cell Signaling), and LIM kinase (no. 3842; Cell Signaling). After being washed, membranes were immersed in horseradish peroxidase-conjugated secondary antibodies (no. 7074, 7076; Cell Signaling). Membranes were incubated with Super Signal West Femto chemiluminescence substrate (Pierce), according to the manufacturer’s instructions. Immunoblots were acquired using the Odyssey Fc Imager (LI-COR Biosciences), Band densities were quantified using Image Studio software (LI-COR Biosciences).

**F/G-actin assay.** The F/G-actin ratio was determined by using the G-actin/F-actin in vivo assay kit (cytoskeleton). Briefly, the G-actin and F-actin pools were separated by ultracentrifugation at 100,000 g during 1 h at 37°C and the supernatant was diluted in 5X SDS sample buffer. The pellet was resuspended in F-actin depolymerizing buffer and kept on ice during 1 h and then diluted with 5X SDS sample buffer. The same amount of supernatant and pellet fraction (10 μl) was loaded on Bio-Rad TGX 4–15% Criterion gels. Proteins were transferred to nitrocellulose membrane using Trans Turbo Blot device (Bio-Rad) for 10 min at 250 V. The membrane was then incubated with rabbit smooth muscle α-actin antibody (provided with the kit; cat. no. AA1001). Anti-rabbit horseradish peroxidase-conjugated secondary antibody (no. 7076; Cell Signaling) was used. Images were acquired using the Odyssey Fc Imager (LI-COR Biosciences).

**Organ culture.** Aortic rings and bladder strips were prepared and organ cultured with 100 μg/ml of losartan (Tocris) at 37°C and 5% CO₂/air in a humidified incubator. Strips were maintained in DMEM/Ham’s F-12 medium (FG4815; Biochrom) supplemented with 50 U/ml penicillin and 50 μg/ml streptomycin (A2213; Biochrom). Strips were harvested for isometric force experiments after 5 days of culture.

**Statistics.** Values are presented as means ± SE. The n values refer to the number of mice. Mann-Whitney or Student’s unpaired t-test (one or two tailed as appropriate) or ANOVA was used to test for significance using GraphPad Prism 5 (GraphPad Software). Concentrations for miR-143/145-deleted phenotype switching in smooth muscle.
The expression level was comparable to the baseline expression of these miRNAs in WT aorta, and that deletion of this cluster results in reduced mean systemic blood pressure (wild type (WT): 153.5 ± 8.9 mmHg vs. KO: 119.5 ± 7.8 mmHg). Since the aim of this study was to compare the effect of miR-143/145 KO in different smooth muscle containing tissues, we first evaluated the baseline expression of these miRNAs in WT aorta, airway, and bladder. The expression level was comparable in aorta and bladder but significantly lower in airways (Fig. 1B). We then assessed agonist-induced contractile function using the α1-adrenergic receptor agonist cirazoline in the aorta and the muscarinic receptor agonist carbachol in the bladder and airways. The contractile response to cirazoline (Fig. 1C) was significantly reduced in aorta from miR-143/145 KO mice. The response to carbachol was unchanged in the bladder (Fig. 1D) as was the cholinergic component of neurogenic activation by electrical field stimulation (data not shown). We also assessed the response to carbachol in bronchioles using precision-cut lung slices (Fig. 1E), but, similar to bladder, no significant effect was seen. Interestingly, depolarization-induced contraction (60 mM KCl) was reduced in aorta and trachea but unaffected in the urinary bladder (Fig. 1, F–H). To test if the reduced ability of the

**RESULTS**

Differential effect of miR-143/145 deletion on contractility in the aorta, airway, and urinary bladder. As previously demonstrated (8), we found that expression of the miR-143/145 cluster was enriched in smooth muscle cells (Fig. 1A) and that deletion of this cluster results in reduced mean systemic blood pressure [wild type (WT): 153.5 ± 8.9 mmHg vs. KO: 119.5 ± 7.8 mmHg]. Since the aim of this study was to compare the effect of miR-143/145 KO in different smooth muscle containing tissues, we first evaluated the baseline expression of these miRNAs in WT aorta, airway, and bladder. The expression level was comparable...
Fig. 2. Opposing effects of miR-143/145 deletion on differentiation marker expression and smooth muscle volume in aorta and bladder. Transcript levels for contractile differentiation markers and transcription factors were examined in the aorta (A; n = 6) and in the bladder (B; n = 6) from WT and miR-143/145 KO mice (Fig. 1, I–K). In summary, this indicates a defect in the contractility in the aorta and in the airways but not in the urinary bladder. We focused henceforth on the aorta and urinary bladder because of the contrasting effects of miR-143/145 deletion on contractility in these tissues.

Fig. 3. Maintained basal actin polymerization in miR-143/145 KO smooth muscle. Rho kinase (ROCK1) expression was analyzed by Western blotting in aorta and bladder from WT and miR-143/145 KO mice (A; n = 6). Western blot analysis was also performed for LIM kinase (LIMK) phosphorylation (LIMK1Thr508/LIMK2Thr505) in the same organs (B; n = 6). C: F/G-actin ratio in aorta and bladder from WT and miR-143/145 KO mice (n = 4). D and E: compiled data on smooth muscle layer thickness in the aorta and bladder (n = 4). *P < 0.05, **P < 0.01, and ***P < 0.001.
Smooth muscle differentiation markers are reduced in the aorta but not in the urinary bladder of miR-143/145 KO mice. Smooth muscle differentiation markers were next analyzed by qRT-PCR. We noted downregulation of mRNAs for myosin heavy chain (Myh11), desmin (Des), and L-type Ca^{2+} channels (Cacna1c) in the aorta of miR-143/145 KO mice (Fig. 2A). Surprisingly, these differentiation markers were unaffected or changed in the opposite direction in the urinary bladder (Fig. 2B). Expression of smooth muscle markers depends on myocardin and SRF-driven transcription. In keeping with the effect on contractile smooth muscle cell markers, we observed a reduction of myocardin and SRF expression in the aorta but upregulation of myocardin and unchanged SRF expression in the urinary bladder (compare Fig. 2, A and B). No significant change in Krüppel-like factor 4 (KLF4) and KLF5 mRNAs was observed in either aorta or bladder. Together, these findings favored the idea that some tissue-specific miRNA target upstream of myocardin might be responsible for altered smooth muscle marker expression in miR-143/145-deficient smooth muscle.

Using conventional histology, we observed a reduction of the thickness of the smooth muscle layer in miR-143/145 KO aorta (Fig. 2, C and D). In the bladder, no significant difference of the smooth muscle layer thickness was seen (Fig. 2, C and E).

The differential effect of miR-143/145 KO is not due to reduced rho activation and actin polymerization or altered KLF4/5 expression. The miR-143/145 cluster has previously been suggested to modulate cytoskeletal dynamics by targeting proteins in the Rho/Rho-kinase pathway (39), which is involved in the regulation of both gene expression and contractile function in smooth muscle (18, 28). Rho activation promotes the expression of contractile genes in smooth muscle by stimulation of actin polymerization and subsequent nuclear translocation of the MRTF, a cofactor for SRF (28). To determine if the Rho/Rho-kinase pathway was differentially affected by miR-143/145 deletion in aorta vs. bladder, we analyzed protein expression of ROCK1 and phosphorylation levels of LIM kinase (LIMK), which is downstream of Rho kinase. The expression level of ROCK1 was significantly higher in aorta compared with bladder and was higher in KO bladder than WT bladder (Fig. 3A). ROCK1 also tended to be higher in KO vs. WT aorta, but this difference did not reach statistical significance. The phosphorylation level of LIMK was increased in KO aorta but unchanged in bladder (Fig. 3B). To directly address if this was associated with a differential effect on actin polymerization in aorta and bladder, we measured the F/G-actin ratio. While the F/G-actin ratio appeared to be higher in the bladder compared with the aorta, no difference was seen between WT and KO in either tissue (Fig. 3C). Thus our findings do not strongly support a primary role of altered actin polymerization in the differential effect of miR-143/145 deletion on contractile differentiation in aorta and bladder.

It has been suggested that the KLF4 can repress the expression of contractile markers in smooth muscle by downregulating myocardin expression and by preventing SRF binding to smooth muscle gene promoters (23). Both KLF4 and KLF 5 have been confirmed as targets for miR-145 in vascular smooth muscle (10, 11). However, we did not find a significant difference in KLF4 expression and only a slight increase KLF 5 in KO bladder (Fig. 3, D and E).

miR-143/145 deletion increases ACE expression in aorta but not in bladder. An additional mechanism by which the miR-143/145 cluster has been proposed to drive smooth muscle contractile differentiation is via repression of ACE. To address if this mechanism might underlie the difference between aorta and bladder, we first performed qRT-PCR for ACE. A significant upregulation of ACE mRNA was seen in aorta but not in the bladder of KO mice (Fig. 4A). Furthermore, the total ACE expression was much higher in the aorta compared with the bladder. The differential effect on ACE in aorta and bladder was seen also when protein expression was analyzed by Western blotting (Fig. 4B). Although the protein expression level of ACE in bladder was low, we were able to detect a band at the correct molecular weight after longer exposure (data not shown).

We next tested if the contractile response to angiotensin II was altered in miR-143/145 KO smooth muscle. As shown in Fig. 4C, the maximal contractile response to angiotensin II was significantly reduced in aorta from miR-143/145 KO mice. No response to angiotensin II was seen in the bladder. This difference is illustrated by the force responses in aorta and bladder at 0.1 μM angiotensin II (Fig. 4D). These findings suggested that lack of impact of miR143/145 on bladder contractility could be due to lack of ACE induction and lack of ACE activity.
responsiveness to angiotensin II. To test this hypothesis, we incubated aortic rings and bladder strips with the angiotensin receptor blocker losartan for 5 days in organ culture and measured contractile function in a myograph. Losartan was not present in the solution during the isometric force recordings. In KO aorta, losartan treatment increased the contractile response to cirazoline (Fig. 5A) and to calyculin A (Fig. 5C). In WT aorta, losartan slightly reduced cirazoline-induced contraction (Fig. 5A). In the bladder, losartan treatment was without effect on both carbachol (Fig. 5B) and calyculin A (Fig. 5D) responses irrespective of genotype. However, following organ culture, an increased contractile response to carbachol was observed in the miR-143/145 KO bladder.

**Differential effects of miR-143/145 deletion on mRNA expression of RGS4 and RGS5 and angiotensin receptors.** Increased production of angiotensin II has been previously associated with biphasic changes in the expression of RGS4 and RGS5 (regulators of a G-protein signaling) (38). Furthermore, reduced expression of RGS4/5 mRNA has previously been suggested to be associated with angiotensin II resistance in miR-143/145 KO vascular smooth muscle (8). We therefore predicted that the mRNA levels of RGS4 and RGS5 would be decreased in miR-143/145 KO aorta. In keeping with this prediction, we found that both mRNAs were reduced in KO vs. WT aorta but not in KO vs. WT bladder (Fig. 6, A and B). Moreover, basal RGS4 and RGS5 expression was lower in bladder vs. aorta (Fig. 6D).

**DISCUSSION**

Our study addressed the role of miR-143/145 for contractility and contractile differentiation in vascular, airway, and bladder smooth muscle. A major finding was that miR-143/145 deletion has varying effects on smooth muscles from different anatomical locations with no or only modest effects on the bladder and major effects on both contractility and differentiation in the aorta. On a general level it is difficult to reconcile these findings with the view that miR-143 and miR-145 influence smooth muscle contractility via hundreds of small effects on targets of relevance for differentiation (8). If this was the case, one would have predicted graded and unidirectional changes in differentiation and contractility in all tissues. This was not seen, and key differentiation markers, such as smooth muscle myosin (Myh11), even changed in opposite directions in aorta and bladder. Therefore, our study favors the view that miR-143 and miR-145 influence contractility and differentiation via a small number of tissue-specific targets.

The procontractile effect of miR-143/145 has been attributed in part to upregulation of myocardin and downregulation of KLF4/5 (10–12, 25). A transcriptional complex consisting of SRF and its cofactors myocardin and MRTFs drives gene expression via so called CArG boxes in the promoter regions of smooth muscle differentiation marker genes (27). This effect is counteracted by KLF4-mediated inhibition of SRF binding to CArG-containing regions (23). Furthermore, KLF5, which is suppressed by miR-145, negatively regulates myocardin expression in smooth muscle (10). Interestingly, myocardin was upregulated in KO bladder (vs. WT bladder) and downregulated in KO aorta, supporting a role for myocardin in the differential regulation of contractile smooth muscle marker expression. However, our findings do not support a role for KLF4/5 in this effect, although we cannot completely exclude...
 reporter assay (8), and subsequent work has confirmed regulation of human ACE expression by both miR-143 and miR-145 (19). Our findings agree well with those prior reports and demonstrate robust upregulation of ACE mRNA and protein (>4-fold) in the aorta of KO mice. Compared with the aorta, ACE was expressed at a lower level in the mouse bladder, providing a straightforward explanation for the lack of effect on contractility in miR-143/145 KO bladder. That is, if the target (e.g., ACE) is not expressed at a sufficient level, then the miRNAs would be ineffective and their loss would not have an impact on cellular function. The ratio between miRNA and target mRNA is an important determinant for the relative effect of a miRNA (22), and the miR145/ACE ratios do indeed differ considerably in bladder and aorta (compare Figs. 1B and 4A). The study of Mukherji et al. (29) demonstrates that an increased mRNA expression saturates the pool of miRNAs leading to dampening of the fold repression. Conversely, when mRNA expression is below a certain threshold, the absolute effect of miRNA inhibition is irrelevant for protein expression and cellular function.

The cleavage product resulting from ACE activity, angiotensin II, has multiple effects on both contractility and differentiation. Apart from inducing acute contraction, it is well known that short-term treatment with angiotensin II promotes hypertrophy and contractile differentiation of smooth muscle cells in culture (13, 35). Therefore, how can increased ACE expression be reconciled with reduced contractile differentiation in the miR-143/145-deficient aorta? To explain this Boettger et al. (8) proposed a model whereby an increase of the local angiotensin II production, not associated with an increased circulating plasma level, induces a state of “angiotensin resistance” (21) with reduced responsiveness not only to angiotensin II but also to other agonists. This model may be extended to explain reduced differentiation provided that the low level of angiotensin II normally present in the arterial wall provides a drive for differentiation that is lost at higher levels of angiotensin II due to angiotensin resistance. Here we found that blockade of angiotensin receptors reduced contractility in the WT aorta, consistent with the view that angiotensin II below a certain threshold is procontractile and can induce myocardin as well as smooth muscle marker expression (40). In KO aorta on the other hand, where angiotensin resistance had been elicited due to the severalfold higher production of angiotensin II, the antagonist improved contractility, presumably because receptor blockade prevented angiotensin resistance. The angiotensin resistance model moreover predicts that miR-143/145 deletion should be without effect on contractility in the absence of ACE induction or in the absence of responsiveness to angiotensin II. Our findings in the bladder confirm this prediction.

Tachyphylaxis (angiotensin resistance) of AT1 receptors is a complex process involving internalization, phosphorylation, arrestin binding, and uncoupling from downstream signaling pathways (17). Unfortunately, receptor internalization is not readily studied in intact tissue with native, untagged, receptors. Prolonged AT1 receptor activation does however, affect expression of RGS4 and RGS5 mRNAs (38). These mRNAs were therefore used as readouts for angiotensin II signaling. Consistent with our finding that ACE induction is specific for aorta, we show that RGS4 and 5 were repressed in KO aorta but not in KO bladder. However, the importance of this effect for the phenotype shift in miR-143/145 KO aorta is likely to be

---

**Fig. 6. Differential effects of miR-143/145 deletion on mRNA expression of RGS4 and RGS5 and angiotensin receptors in aorta vs. bladder.**

A and B: mRNA expression of the regulator of G signaling (Rgs) 4 and 5 in aorta and bladder from WT and miR-143/145 KO mice (*n* = 6). C and D: mRNA expression of AT1 and AT2 in aorta and bladder from WT and miR-143/145 KO mice (*n* = 6). All targets were normalized to 18S and are shown relative to mRNA expression in WT aorta. *P* < 0.05, **P* < 0.01, and ***P* < 0.001.

---

This possibility. A mechanism upstream of myocardin that depends on a tissue-specific target of miR-143/145 provides a more likely primary explanation.

Previous studies (26) including work by us (1, 2, 41) have shown that actin polymerization is an important stimulus for contractile differentiation in smooth muscle. The mechanism behind this effect involves sequestration of MRTF in the cytoplasm by monomeric G-actin (28). When G-actin is incorporated into filaments (F-actin), MRTF is liberated and translocates to the nucleus where SRF-dependent transcription of contractile and cytoskeletal genes is stimulated (37). Prior work implicated changes in cytoskeletal dynamics as important factors behind the effects of miR-143/145 on smooth muscle cell fate (5, 39). However, herein we did not find a significant difference in actin polymerization after deletion of miR-143/145 in either aortic or bladder smooth muscle. Our findings therefore do not strongly support altered basal actin polymerization as the reason for the differential impact of miR-143/145 deletion on contractility in aorta and bladder.

ACE was originally found to be upregulated in miR-143/145 KO mice by Boettger et al. (8) using mass spectrometry. Sequences in the 3′-untranslated region of mouse ACE were found to confer sensitivity to miR-145 overexpression in a

---

**AJP-Cell Physiol** • doi:10.1152/ajpcell.00250.2014 • www.ajpcell.org
rather complex and will require further investigation. Available evidence regarding AT1 receptor mRNA in tachyphylaxis has demonstrated a transient increase followed by sustained repression (31), but the length of these phases could depend on angiotensin II concentration. Here we found that the type 1 receptor was modestly upregulated in KO aorta. This effect was not seen in bladder, further supporting our view that overall changes in contractility associate with changes in angiotensin II signaling.

Interestingly, contractile function in miR-143/145 KO aorta was partly rescued following organ culture in the presence of the AT1 receptor antagonist losartan. While our work substantiates an association between altered ACE expression/angiotensin II signaling and loss of contractility in miR-143/145 KO aorta, we cannot associate this with certainty to the AT1 receptor. To maximize the rescue effect in organ culture, we used a concentration of losartan that may have affected AT2 receptors in addition to AT1 receptors. Furthermore, it is quite possible that other peptides cleaved by ACE (such as bradykinin or angiotensin I–7) contribute in the KO setting. It is also interesting to note that AT2 receptor levels were much higher in bladder than in aorta, contrasting with AT1 receptor levels, which were similar. AT2 receptors are considered to counteract the effects of AT1 receptors in many regards (9). High AT2 receptor expression in the bladder may thus impart insensitivity to angiotensin II stimulation and counteract effects of miR-143/145 deletion.

Our prior work using smooth muscle-specific dicer KO mice (32) documented three major phenotypes in the bladder. We reported 1) increased matrix area between smooth muscle cells, 2) reduced depolarization-induced contraction, and 3) a pronounced impairment of the cholinergic component of neurogenic bladder activation. We have subsequently attributed the increased matrix area in the dicer KO bladder to miR-29 (14), which targets multiple extracellular matrix proteins, but the miRNAs responsible for the reduction of depolarization-induced contraction and impaired neurogenic activation have not been identified. We show here that depolarization-induced contraction and neurogenic activation is maintained in miR-143/145 KO bladders, arguing that miRNAs other than miR-143/145 must be responsible for reduced depolarization-induced contraction and neurogenic activation in dicer KO bladders.

One aim of our study was to also assess the effect of miR-143/145 deletion on airway function. These experiments revealed clear-cut reductions of both depolarization- and phosphatase inhibitor-induced contraction. The airways therefore behave like the aorta in regard to miR-143/145 deletion, and ACE is known to be expressed in the airways. This is illustrated by the common adverse effect referred to as “ACE-inhibitor cough” (16), which is due to the rising accumulation of bradykinin in the airways. We did not include airway preparations in our further analyses due to the apparent similarity with the aorta, but these results indicate that miR-143/145 play roles for smooth muscle contractility beyond the vascular system.

In summary, we have shown that tissue-specific targets are decisive for the effects of miR-143/145 on smooth muscle differentiation and that ACE is an important target for miR-143/145-dependent phenotype switching. These findings may have implications for our understanding of phenotypic modulation of smooth muscle cells in disease. Furthermore, our results demonstrate that one miRNA cluster can have contrasting effects in the same cell type from different organs. It remains to be investigated if miR-143/145 and other miRNAs can have varying effects also in different vascular beds. This would have implications for the use of miRNA-targeted therapies in treatment of vascular disease.

GRANTS

This work was supported by the Swedish Research Council; the Swedish Heart and Lung Foundation, the Crafoord Foundation; the Royal Physiographic Society; the Åke Wiberg Foundation; Olle Engkvist Byggmästare Foundation, the Jeansson Foundation; the Tore Nilson Foundation; the Greta and Johan Kock Foundation; the Magnus Bergvall Foundation, the Zoegas foundation and the Lars Hierta Memorial Foundation. K. Turczyńska was in part supported by the European Union FP7 Marie Curie Initial Training Network Small Artery Remodeling (SmArt).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS


REFERENCES

Differential effects of miR-143/145 deletion in smooth muscle


